Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Sells $374,891.04 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart sold 12,336 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.39, for a total transaction of $374,891.04. Following the completion of the sale, the director now owns 12,546 shares of the company’s stock, valued at $381,272.94. This trade represents a 49.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kiniksa Pharmaceuticals Stock Up 1.5%

KNSA stock opened at $30.22 on Thursday. The business’s 50-day moving average price is $24.80 and its 200-day moving average price is $22.08. The stock has a market cap of $2.21 billion, a P/E ratio of -215.84 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.69.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the prior year, the business posted ($0.25) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 72.5% compared to the same quarter last year. On average, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Braidwell LP increased its position in Kiniksa Pharmaceuticals by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock worth $68,289,000 after purchasing an additional 557,934 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Kiniksa Pharmaceuticals by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after buying an additional 151,604 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 170.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock worth $22,961,000 after buying an additional 651,700 shares during the last quarter. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after buying an additional 54,361 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on KNSA shares. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wall Street Zen cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 6th. Finally, Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.